# KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer

> **NCT04474119** · PHASE3 · UNKNOWN · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 482 (actual)

## Conditions studied

- Squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** KN046
- **DRUG:** KN046 placebo

## Key facts

- **NCT ID:** NCT04474119
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-14
- **Primary completion:** 2022-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 482 (ACTUAL)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04474119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04474119, "KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04474119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*